944842-54-0 MDL NO.:
Synonyms: (R)-2-((2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide;VX509; VX-509; VX 509 ; VRT831509 ; VRT-831509 ; VRT 831509 . PubChem CID 59422203. Decernotinib; Adelatinib.
1) All the descriptions are subject to CAS number.
2) Please feel free to contact us if you need further assistance.
You can send e-mail to firstname.lastname@example.org,or,send your inquiry by click on the"Inquiry" button.
3) We will respond to you within 24 hours.
Decernotinib, also known as VX-509 or VRT-831509 or adelatinib, is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex. VX-509 may represent a new approach to treating an underlying disease mechanism that triggers inflammation in a number of debilitating diseases, including RA. In immune-mediated diseases, JAK3 is an essential component of the immune signaling cascade. This cascade ultimately contributes to abnormal immune response that results in chronic inflammation and, in the case of RA, irreversible damage to cartilage and bones.